|
1
|
Scaltriti M and Baselga J: The epidermal
growth factor receptor pathway: a model for targeted therapy. Clin
Cancer Res. 12:5268–5272. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mendelsohn J and Baselga J: Epidermal
growth factor receptor targeting in cancer. Semin Oncol.
33:369–385. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Schubbert S, Shannon K and Bollag G:
Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ginesta MM, Mora J, Mayor R, et al:
Genetic and epigenetic markers in the evaluation of pancreatic
masses. J Clin Pathol. 66:192–197. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mascaux C, Iannino N, Martin B, et al: The
role of RAS oncogene in survival of patients with lung cancer: a
systematic review of the literature with meta-analysis. Br J
Cancer. 92:131–139. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kohlmann A, Grossmann V, Klein HU, et al:
Next-generation sequencing technology reveals a characteristic
pattern of molecular mutations in 72.8% of chronic myelomonocytic
leukemia by detecting frequent alterations in TET2, CBL, RAS, and
RUNX1. J Clin Oncol. 28:3858–3865. 2010.PubMed/NCBI
|
|
8
|
Uhara H, Ashida A, Koga H, et al:
NRAS mutations in primary and metastatic melanomas of
Japanese patients. Int J Clin Oncol. June 6–2013.(Epub ahead of
print).
|
|
9
|
De Roock W, Claes B, Bernasconi D, et al:
Effects of KRAS, BRAF, NRAS, and PIK3CA
mutations on the efficacy of cetuximab plus chemotherapy in
chemotherapy-refractory metastatic colorectal cancer: a
retrospective consortium analysis. Lancet Oncol. 11:753–762.
2010.
|
|
10
|
Vaughn CP, Zobell SD, Furtado LV, Baker CL
and Samowitz WS: Frequency of KRAS, BRAF, and
NRAS mutations in colorectal cancer. Genes Chromosomes
Cancer. 50:307–312. 2011.PubMed/NCBI
|
|
11
|
Loupakis F, Ruzzo A, Cremolini C, et al:
KRAS codon 61, 146 and BRAF mutations predict
resistance to cetuximab plus irinotecan in KRAS codon 12 and
13 wild-type metastatic colorectal cancer. Br J Cancer.
101:715–721. 2009. View Article : Google Scholar
|
|
12
|
Irahara N, Baba Y, Nosho K, et al:
NRAS mutations are rare in colorectal cancer. Diagn Mol
Pathol. 19:157–163. 2010. View Article : Google Scholar
|
|
13
|
Seymour MT, Brown SR, Middleton G, et al:
Panitumumab and irinotecan versus irinotecan alone for patients
with KRAS wild-type, fluorouracil-resistant advanced
colorectal cancer (PICCOLO): a prospectively stratified randomised
trial. Lancet Oncol. 14:749–759. 2013.PubMed/NCBI
|
|
14
|
Smith CG, Fisher D, Claes B, et al:
Somatic profiling of the epidermal growth factor receptor pathway
in tumors from patients with advanced colorectal cancer treated
with chemotherapy ± cetuximab. Clin Cancer Res. 19:4104–4113.
2013.PubMed/NCBI
|
|
15
|
Farina-Sarasqueta A, van Lijnschoten G,
Moerland E, et al: The BRAF V600E mutation is an independent
prognostic factor for survival in stage II and stage III colon
cancer patients. Ann Oncol. 21:2396–2402. 2010. View Article : Google Scholar
|
|
16
|
Van Cutsem E, Kohne CH, Hitre E, et al:
Cetuximab and chemotherapy as initial treatment for metastatic
colorectal cancer. N Engl J Med. 360:1408–1417. 2009.PubMed/NCBI
|
|
17
|
Bokemeyer C, Bondarenko I, Makhson A, et
al: Fluorouracil, leucovorin, and oxaliplatin with and without
cetuximab in the first-line treatment of metastatic colorectal
cancer. J Clin Oncol. 27:663–671. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Karapetis CS, Khambata-Ford S, Jonker DJ,
et al: K-ras mutations and benefit from cetuximab in
advanced colorectal cancer. N Engl J Med. 359:1757–1765. 2008.
View Article : Google Scholar
|
|
19
|
Douillard JY, Siena S, Cassidy J, et al:
Randomized, phase III trial of panitumumab with infusional
fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4
alone as first-line treatment in patients with previously untreated
metastatic colorectal cancer: the PRIME study. J Clin Oncol.
28:4697–4705. 2010. View Article : Google Scholar
|
|
20
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in
patients with metastatic colorectal cancer. J Clin Oncol.
26:1626–1634. 2008.PubMed/NCBI
|
|
21
|
Douillard JY, Oliner KS, Siena S, et al:
Panitumumab-FOLFOX4 treatment and RAS mutations in
colorectal cancer. N Engl J Med. 369:1023–1034. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Samowitz WS, Sweeney C, Herrick J, et al:
Poor survival associated with the BRAF V600E mutation in
microsatellite-stable colon cancers. Cancer Res. 65:6063–6069.
2005.PubMed/NCBI
|
|
23
|
Roth AD, Tejpar S, Delorenzi M, et al:
Prognostic role of KRAS and BRAF in stage II and III
resected colon cancer: results of the translational study on the
PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 28:466–474.
2010.
|
|
24
|
Imamura Y, Morikawa T, Liao X, et al:
Specific mutations in KRAS codons 12 and 13, and patient
prognosis in 1075 BRAF wild-type colorectal cancers. Clin
Cancer Res. 18:4753–4763. 2012.PubMed/NCBI
|
|
25
|
Lochhead P, Kuchiba A, Imamura Y, et al:
Microsatellite instability and BRAF mutation testing in
colorectal cancer prognostication. J Natl Cancer Inst.
105:1151–1156. 2013.PubMed/NCBI
|
|
26
|
Gavin PG, Colangelo LH, Fumagalli D, et
al: Mutation profiling and microsatellite instability in stage II
and III colon cancer: an assessment of their prognostic and
oxaliplatin predictive value. Clin Cancer Res. 18:6531–6541. 2012.
View Article : Google Scholar
|
|
27
|
Ogino S, Shima K, Meyerhardt JA, et al:
Predictive and prognostic roles of BRAF mutation in stage
III colon cancer: results from intergroup trial CALGB 89803. Clin
Cancer Res. 18:890–900. 2012.PubMed/NCBI
|
|
28
|
Akagi K, Uchibori R, Yamaguchi K, Kurosawa
K, Tanaka Y and Kozu T: Characterization of a novel oncogenic
K-ras mutation in colon cancer. Biochem Biophys Res Commun.
352:728–732. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Asaka S, Arai Y, Nishimura Y, et al:
Microsatellite instability-low colorectal cancer acquires a
KRAS mutation during the progression from Dukes’ A to Dukes’
B. Carcinogenesis. 30:494–499. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ishikubo T, Nishimura Y, Yamaguchi K, et
al: The clinical features of rectal cancers with high-frequency
microsatellite instability (MSI-H) in Japanese males. Cancer Lett.
216:55–62. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Andreyev HJ, Norman AR, Cunningham D,
Oates JR and Clarke PA: Kirsten ras mutations in patients with
colorectal cancer: the multicenter ‘RASCAL’ study. J Natl Cancer
Inst. 90:675–684. 1998.
|
|
32
|
Yokota T, Ura T, Shibata N, et al:
BRAF mutation is a powerful prognostic factor in advanced
and recurrent colorectal cancer. Br J Cancer. 104:856–862. 2011.
View Article : Google Scholar
|
|
33
|
Oh JR, Kim DW, Lee HS, et al:
Microsatellite instability testing in Korean patients with
colorectal cancer. Fam Cancer. 11:459–466. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Yamauchi M, Morikawa T, Kuchiba A, et al:
Assessment of colorectal cancer molecular features along bowel
subsites challenges the conception of distinct dichotomy of
proximal versus distal colorectum. Gut. 61:847–854. 2012.
View Article : Google Scholar
|
|
35
|
Richman SD, Seymour MT, Chambers P, et al:
KRAS and BRAF mutations in advanced colorectal cancer
are associated with poor prognosis but do not preclude benefit from
oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin
Oncol. 27:5931–5937. 2009. View Article : Google Scholar
|
|
36
|
Phipps AI, Buchanan DD, Makar KW, et al:
KRAS-mutation status in relation to colorectal cancer survival: the
joint impact of correlated tumour markers. Br J Cancer.
108:1757–1764. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tol J, Koopman M, Cats A, et al:
Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal
cancer. N Engl J Med. 360:563–572. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Bokemeyer C, Bondarenko I, Hartmann JT, et
al: Efficacy according to biomarker status of cetuximab plus
FOLFOX-4 as first-line treatment for metastatic colorectal cancer:
the OPUS study. Ann Oncol. 22:1535–1546. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Fornaro L, Lonardi S, Masi G, et al:
FOLFOXIRI in combination with panitumumab as first-line treatment
in quadruple wild-type (KRAS, NRAS, HRAS,
BRAF) metastatic colorectal cancer patients: a phase II
trial by the Gruppo Oncologico Nord Ovest (GONO). Ann Oncol.
24:2062–2067. 2013. View Article : Google Scholar : PubMed/NCBI
|
